Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.

Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file ...

23andMe, known for its at-home DNA testing kits and genetic profiles, said it will file a Form 25 Notification of Delisting with the SEC "on or about June 6," according to a company statement.

Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC. About 23andMe 23andMe is a genetics-led consumer healthcare and biotechnology ...

The completion of the Nasdaq delisting process will enable 23andMe to proceed with the SEC deregistration. 23andMe, known for its direct-to-consumer genetic testing kits, has faced a number of ...

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron ...